Amarantus BioSciences, Inc. (OTCBB:AMBS), a biotechnology company developing Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF), a first-in-class disease–modifying therapeutic protein, today announced a commitment by Brewer Sports International (BSI) to fund a pre-clinical study evaluating MANF’s potential as a treatment for Traumatic Brain Injury (TBI). This funding will support the collaboration recently announced between Amarantus and Banyan Biomarkers.

“Concussion management is a serious issue affecting athletes in a wide variety of sports and other activities, and we are grateful for this initial contribution from Brewer Sports to test MANF against this debilitating condition,” said Gerald Commissiong, President and CEO of Amarantus. “As a former professional athlete, I have a vested interest in this area of focus for Amarantus and look forward to reporting on the results in early 2012.”

As a multi-faceted sports management and financial services firm, Brewer Sports International is focused on providing tailored solutions to emerging sports and wellness-related companies through its vast network. BSI’s CEO Jack Brewer played for five years in the National Football League, retiring in 2007. Many of BSI’s professional athlete clientele participate in sports where concussions are prevalent, and the firm maintains a strong desire to advance research and awareness in the area. The Amarantus study targeting TBI fits this focus and if the initial study is positive, Brewer will help Amarantus identify additional funding channels to support further studies.

“As an ex-NFL player I personally have experienced hundreds of violent collisions throughout my career and also have several teammates and friends who suffer the lasting effects of Traumatic Brain Injury,” said Jack Brewer, CEO of Brewer Sports International. “This is a passion of mine and BSI is committed to helping advance TBI research and development. I am hopeful that our support and this collaboration will help raise awareness and establish new technology for the treatment of brain injury and concussions.”

About MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor)

MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. The lead MANF product development effort is centered on a therapy for Parkinson's disease, currently funded by a research grant from the Michael J. Fox Foundation for Parkinson’s Research. The Company also owns an inventory of 88 cell lines referred to as “PhenoGuard Cell Lines.” MANF was the first therapeutic protein discovered from a PhenoGuard Cell Line. It is anticipated that additional therapeutic proteins useful for various therapeutic approaches to the Central Nervous System (CNS) will be identified from the Company’s inventory of PhenoGuard Cell Lines.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson’s disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit

About Brewer Sports International

Brewer Sports International (BSI) offers a boutique of sports lending, corporate advisory and entertainment services for professional athletes, sports agencies, public and private corporations and various partners including international organizations, governments and NGOs. Based in Minneapolis, with offices in New York, Boca Raton and Beijing, BSI was founded by Jack Brewer, a five-year National Football League (NFL) veteran and former team captain on three NFL teams. Additionally, BSI has created a unique financial services platform that is offered to professional athletes and sports agencies, as well as high net worth individuals and businesses touching professional sports. BSI takes pride in building value for its clients through sports and entertainment. For more information, please visit

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus’ PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.